Search research articles
Contact Us
Filters
Showing results (881-890 of 1,038) with videos related to
Page
of 104
Sort By:
Blood Advances
|
October 6, 2020
Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma
Constantine S Tam, Hang Quach, Andrew Nicol, et al.
The Lancet. Haematology
|
March 5, 2017
Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial
Jeffrey A Jones, Tadeusz Robak, Jennifer R Brown, et al.
Journal of Vascular Surgery
|
January 11, 2007
Results of the national pilot screening program for venous disease by the American Venous Forum
Robert B McLafferty, Joanne M Lohr, Joseph A Caprini, et al.
Leukemia
|
May 29, 2010
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study
S K Kumar, I Flinn, S J Noga, et al.
Hemasphere
|
November 15, 2019
Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Steven E Coutre, Ian W Flinn, Sven de Vos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2025
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/<i>TP53</i> Mutation: SEQUOIA Arm D Results
Mazyar Shadman, Talha Munir, Shuo Ma, et al.
The Lancet. Oncology
|
February 25, 2018
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
Howard A Burris, Ian W Flinn, Manish R Patel, et al.
American Journal of Hematology
|
December 29, 2018
Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study
Paul A Hamlin, Ian W Flinn, Nina Wagner-Johnston, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
June 11, 2013
Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia
Chris L Pashos, Christopher R Flowers, Neil E Kay, et al.
The European Respiratory Journal
|
July 4, 2024
Blood transcriptomic signatures for symptomatic tuberculosis in an African multicohort study
Vanessa Mwebaza Muwanga, Simon C Mendelsohn, Vinzeigh Leukes, et al.
Page
of 104
Search research articles
Search
Showing results (881-890 of 1,038) with videos related to
Sort By:
Page
of 104
Blood Advances
|
October 6, 2020
Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma
Constantine S Tam, Hang Quach, Andrew Nicol, et al.
The Lancet. Haematology
|
March 5, 2017
Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial
Jeffrey A Jones, Tadeusz Robak, Jennifer R Brown, et al.
Journal of Vascular Surgery
|
January 11, 2007
Results of the national pilot screening program for venous disease by the American Venous Forum
Robert B McLafferty, Joanne M Lohr, Joseph A Caprini, et al.
Leukemia
|
May 29, 2010
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study
S K Kumar, I Flinn, S J Noga, et al.
Hemasphere
|
November 15, 2019
Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Steven E Coutre, Ian W Flinn, Sven de Vos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2025
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/<i>TP53</i> Mutation: SEQUOIA Arm D Results
Mazyar Shadman, Talha Munir, Shuo Ma, et al.
The Lancet. Oncology
|
February 25, 2018
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
Howard A Burris, Ian W Flinn, Manish R Patel, et al.
American Journal of Hematology
|
December 29, 2018
Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study
Paul A Hamlin, Ian W Flinn, Nina Wagner-Johnston, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
June 11, 2013
Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia
Chris L Pashos, Christopher R Flowers, Neil E Kay, et al.
The European Respiratory Journal
|
July 4, 2024
Blood transcriptomic signatures for symptomatic tuberculosis in an African multicohort study
Vanessa Mwebaza Muwanga, Simon C Mendelsohn, Vinzeigh Leukes, et al.
Page
of 104